Nouscom

18 articles about Nouscom

• Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

  11/14/2023

  Nouscom announced the completion of its oversubscribed Series C equity financing raising €67.5 million from a syndicate of renowned international healthcare investors.

• Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023

  4/18/2023

  Nouscom announced new translational and biomarker data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma.

• Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy

  3/15/2023

  Nouscom announced that new translational data obtained from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma has been accepted for presentation in a Late-Breaking session at the 2023 American Association for Cancer Research Annual Meeting.

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
• 

  Clinical Catch-Up: AACR, AAN and COVID-19

  4/18/2022

  It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
• 

  AACR: Monday's Stars Include Affimed, Hoth and Blueprint

  4/11/2022

  The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
• 

  Clinical Catch-Up: November 8-12

  11/15/2021

  It was another busy week for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
• 

  Clinical Catch-Up: March 8-12

  3/15/2021

  It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
• 

  BioSpace Movers & Shakers, Feb. 28

  2/28/2020

  Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.
• 

  BioSpace Global Roundup, Dec. 12

  12/12/2019

  Companies from across the globe provide updates to their business and pipelines.
• 

  BioSpace Global Roundup, June 6

  6/6/2019

  Companies from across the globe share updates on their pipelines and growth strategies.

• Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

  11/5/2018

  Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.

• 

  Biotech Leadership Transformations: Week of May 28th

  6/3/2018

  There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.

• NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

  11/13/2017

  Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics' NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials.

• 

  Two-Year Old Biotech NousCom Nabs $49M to Fund New Drug Into Clinic

  11/6/2017

  The round was led by new investor Abingworth with participation from another new investor, 5AM Ventures, LSP and Versant Ventures.

• Nouscom Appoints New Chief Operating Officer And Strengthens The Board Of Directors

  9/26/2016